Amgen (AMGN) came out with quarterly earnings of $5.58 per share, beating the Zacks Consensus Estimate of $5.11 per share. This compares to earnings of $4.96 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.20%. A quarter ago, it was expected that this world's largest biotech drugmaker would post earnings of $4.93 per share when it actually produced earnings of $4.97, delivering a surprise of 0.81%.Over the last four quarters ...

Exhibit 99.1 One Amgen Center Drive Thousand Oaks, CA 91320-1799 | --- | --- | |--------------|----------------------------------------| | | | | News Release | Telephone 805-447-1000 www.amgen.com | AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Oct. 30, 2024) - Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our business. We continue to invest hea ...

THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our business. We continue to invest heavily in our rapidly advancing pipeline, with a focus on delivering innovative therapies across our core therapeutic areas," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the third quarter, total r ...

There are reasons beyond the dividends to invest in these stocks.Everyone loves the concept of passive income. Nothing beats getting paid without lifting a finger. Dividends can be a great source of passive income, but those who decide to reinvest the payouts are engaging in what might be called passive investing. It's a compelling strategy: Strategically reinvesting dividends improves long-term returns. Just check the performance of the S&P 500 since 2000, without and with dividends reinvested.  Choosing a ...

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The dividend will be paid on December 9, 2024, to all stockholders of record as of the close of business on November 18, 2024. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there. I last covered Amgen (NASDAQ: AMGN ) for Seeking Alpha in early August, reviewing the California based Pharma giant's Q2 earnings. I gave its stock a "Buy" rating, however ...

Analysts on Wall Street project that Amgen (AMGN) will announce quarterly earnings of $5.11 per share in its forthcoming report, representing an increase of 3% year over year. Revenues are projected to reach $8.52 billion, increasing 23.4% from the same quarter last year. The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates duri ...

THOUSAND OAKS, Calif., Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.Live audio of the conferenc ...

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on approved drugs and drug candidates in research and development as biosimilar antibodies of Prolia & Xgeva (denosumab).This product consists of: Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.Projec ...

Amgen (AMGN) will report third-quarter 2024 results on Oct. 30, after market close. In the last reported quarter, the company beat earnings expectations by 0.81%.The Zacks Consensus Estimate for sales and earnings is pegged at $8.51 billion and $5.11 per share, respectively.Factors to Consider for AmgenAmgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Prolia and Blincyto among others. However, prices of most products are expected to continue to ...